APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Refractory Cough (CRC) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chronic Refractory Cough (CRC) Treatment Market Outlook and Growth Opportunities 2026

19 December 2025196 pages

Choose your research edition.

Industry ResearchChronic Refractory Cough (CRC) Treatment Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Refractory Cough (CRC) Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Chronic Refractory Cough (CRC) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Refractory Cough (CRC) Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Refractory Cough (CRC) Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chronic Refractory Cough (CRC) Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chronic Refractory Cough (CRC) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Refractory Cough (CRC) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Refractory Cough (CRC) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chronic Refractory Cough (CRC) Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chronic Refractory Cough (CRC) Treatment market include Shionogi, Merck, Respivant Sciences, Nerre Therapeutics, Bellus Health and Attenua, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Chronic Refractory Cough (CRC) Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Refractory Cough (CRC) Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Refractory Cough (CRC) Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Chronic Refractory Cough (CRC) Treatment market.

Chronic Refractory Cough (CRC) Treatment Segment by Company

Shionogi

Merck

Respivant Sciences

Nerre Therapeutics

Bellus Health

Attenua

Chronic Refractory Cough (CRC) Treatment Segment by Type

Speech Therapy

Physiotherapy

Chronic Refractory Cough (CRC) Treatment Segment by Application

Hospital

Clinic

Others

Chronic Refractory Cough (CRC) Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Chronic Refractory Cough (CRC) Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Chronic Refractory Cough (CRC) Treatment key companies, revenue, market share, and recent developments.

3. To split the Chronic Refractory Cough (CRC) Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Chronic Refractory Cough (CRC) Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chronic Refractory Cough (CRC) Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Chronic Refractory Cough (CRC) Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Refractory Cough (CRC) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Refractory Cough (CRC) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Refractory Cough (CRC) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Refractory Cough (CRC) Treatment industry.

Chapter 3: Detailed analysis of Chronic Refractory Cough (CRC) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Chronic Refractory Cough (CRC) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Chronic Refractory Cough (CRC) Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chronic Refractory Cough (CRC) Treatment Industry Trends Table 2. Chronic Refractory Cough (CRC) Treatment Industry Drivers Table 3. Chronic Refractory Cough (CRC) Treatment Industry Opportunities and Challenges Table 4. Chronic Refractory Cough (CRC) Treatment Industry Restraints Table 5. Global Chronic Refractory Cough (CRC) Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chronic Refractory Cough (CRC) Treatment Revenue Share by Company (2021-2026) Table 7. Global Chronic Refractory Cough (CRC) Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Chronic Refractory Cough (CRC) Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Chronic Refractory Cough (CRC) Treatment Company, Product Type & Application Table 10. Global Chronic Refractory Cough (CRC) Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Chronic Refractory Cough (CRC) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Speech Therapy Table 15. Significant Companies of Physiotherapy Table 16. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type (2021-2026) Table 20. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application (2021-2026) Table 28. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application (2027-2032) Table 29. Global Chronic Refractory Cough (CRC) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Region (2021-2026) Table 32. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Region (2027-2032) Table 34. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Chronic Refractory Cough (CRC) Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Chronic Refractory Cough (CRC) Treatment Sales Value Market Share by Country (2027-2032) Table 39. Shionogi Company Information Table 40. Shionogi Business Overview Table 41. Shionogi Chronic Refractory Cough (CRC) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Shionogi Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 43. Shionogi Recent Development Table 44. Merck Company Information Table 45. Merck Business Overview Table 46. Merck Chronic Refractory Cough (CRC) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Merck Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 48. Merck Recent Development Table 49. Respivant Sciences Company Information Table 50. Respivant Sciences Business Overview Table 51. Respivant Sciences Chronic Refractory Cough (CRC) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Respivant Sciences Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 53. Respivant Sciences Recent Development Table 54. Nerre Therapeutics Company Information Table 55. Nerre Therapeutics Business Overview Table 56. Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 58. Nerre Therapeutics Recent Development Table 59. Bellus Health Company Information Table 60. Bellus Health Business Overview Table 61. Bellus Health Chronic Refractory Cough (CRC) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Bellus Health Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 63. Bellus Health Recent Development Table 64. Attenua Company Information Table 65. Attenua Business Overview Table 66. Attenua Chronic Refractory Cough (CRC) Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Attenua Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 68. Attenua Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. Chronic Refractory Cough (CRC) Treatment Product Image Figure 2. Global Chronic Refractory Cough (CRC) Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Refractory Cough (CRC) Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Chronic Refractory Cough (CRC) Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Speech Therapy Image Figure 8. Physiotherapy Image Figure 9. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Chronic Refractory Cough (CRC) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Speech Therapy
  • Physiotherapy
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Shionogi
  • Merck
  • Respivant Sciences
  • Nerre Therapeutics
  • Bellus Health
  • Attenua

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chronic Refractory Cough (CRC) Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chronic Refractory Cough (CRC) Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Chronic Refractory Cough (CRC) Treatment Market Dynamics
  1. 2.1 Chronic Refractory Cough (CRC) Treatment Industry Trends
  2. 2.2 Chronic Refractory Cough (CRC) Treatment Industry Drivers
  3. 2.3 Chronic Refractory Cough (CRC) Treatment Industry Opportunities and Challenges
  4. 2.4 Chronic Refractory Cough (CRC) Treatment Industry Restraints
3 Chronic Refractory Cough (CRC) Treatment Market by Company
  1. 3.1 Global Chronic Refractory Cough (CRC) Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Chronic Refractory Cough (CRC) Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Chronic Refractory Cough (CRC) Treatment Company Ranking (2024-2026)
  4. 3.4 Global Chronic Refractory Cough (CRC) Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Chronic Refractory Cough (CRC) Treatment Company Product Type and Application
  6. 3.6 Global Chronic Refractory Cough (CRC) Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Chronic Refractory Cough (CRC) Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Chronic Refractory Cough (CRC) Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Chronic Refractory Cough (CRC) Treatment Market by Type
  1. 4.1 Chronic Refractory Cough (CRC) Treatment Type Introduction
  2. 4.1.1 Speech Therapy
  3. 4.1.2 Physiotherapy
  4. 4.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type
  5. 4.2.1 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type (2021-2032)
5 Chronic Refractory Cough (CRC) Treatment Market by Application
  1. 5.1 Chronic Refractory Cough (CRC) Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application
  6. 5.2.1 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application (2021-2032)
6 Chronic Refractory Cough (CRC) Treatment Regional Value Analysis
  1. 6.1 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Chronic Refractory Cough (CRC) Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Chronic Refractory Cough (CRC) Treatment Sales Value Share by Country, 2025 VS 2032
7 Chronic Refractory Cough (CRC) Treatment Country-level Value Analysis
  1. 7.1 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Chronic Refractory Cough (CRC) Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Chronic Refractory Cough (CRC) Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Chronic Refractory Cough (CRC) Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Chronic Refractory Cough (CRC) Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shionogi
  2. 8.1.1 Shionogi Company Information
  3. 8.1.2 Shionogi Business Overview
  4. 8.1.3 Shionogi Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shionogi Chronic Refractory Cough (CRC) Treatment Product Portfolio
  6. 8.1.5 Shionogi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Chronic Refractory Cough (CRC) Treatment Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Respivant Sciences
  14. 8.3.1 Respivant Sciences Company Information
  15. 8.3.2 Respivant Sciences Business Overview
  16. 8.3.3 Respivant Sciences Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Respivant Sciences Chronic Refractory Cough (CRC) Treatment Product Portfolio
  18. 8.3.5 Respivant Sciences Recent Developments
  19. 8.4 Nerre Therapeutics
  20. 8.4.1 Nerre Therapeutics Company Information
  21. 8.4.2 Nerre Therapeutics Business Overview
  22. 8.4.3 Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Product Portfolio
  24. 8.4.5 Nerre Therapeutics Recent Developments
  25. 8.5 Bellus Health
  26. 8.5.1 Bellus Health Company Information
  27. 8.5.2 Bellus Health Business Overview
  28. 8.5.3 Bellus Health Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bellus Health Chronic Refractory Cough (CRC) Treatment Product Portfolio
  30. 8.5.5 Bellus Health Recent Developments
  31. 8.6 Attenua
  32. 8.6.1 Attenua Company Information
  33. 8.6.2 Attenua Business Overview
  34. 8.6.3 Attenua Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Attenua Chronic Refractory Cough (CRC) Treatment Product Portfolio
  36. 8.6.5 Attenua Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst